Ono Pharmaceutical Announces Changes in Investigational AIDS Drug Development Program.Tokyo, Japan, Sept 26, 2005 - (JCNN JCNN Japan Corporate News Network ) - Ono Pharmaceutical has decided to change its development program for ONO-41028/873140, an investigational drug for AIDS treatment. Specifically, the company's development partner GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ) has observed elevated liver function test values (AST (AST Computer, Irvine, CA) A PC manufacturer founded in 1980 by Albert Wong, Safi Quershey and Tom Yuen (A, S and T). It offered a complete line of PCs that sold through its dealer channel. , ALT and total bilirubin Bilirubin The predominant orange pigment of bile. It is the major metabolic breakdown product of heme, the prosthetic group of hemoglobin in red blood cells, and other chromoproteins such as myoglobin, cytochrome, and catalase. ) in the recent Phase IIb studies conducted in North America and Europe. As a result, GSK has decided to terminate Phase IIB studies in HIV-positive patients who have never taken any AIDS drug. Further, GSK has made some changes to the protocol for phase III clinical studies in HIV-positive patients who have been treated with AIDS drugs. ONO-4128/873140 is a CCR5 receptor antagonist. Ono Pharmaceutical and GSK entered into a licensing agreement for the agent in December 2002. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion